/C O R R E C T I O N — Vital Therapies, Inc./

SAN DIEGO, September 16, 2010 - In the news release, Vital Therapies Expands SILVER Trial to Saudi
Arabia, issued earlier today by Vital Therapies, Inc. over PR Newswire, we
are advised by the company that the there are multiple changes to the
release as originally issued inadvertently.
Complete, corrected release follows:

Vital Therapies Expands SILVER Trial to Saudi Arabia

- Bioartificial Liver Trial Now at Halfway Point

Vital Therapies, Inc., (VTI) is pleased to announce that the first
subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of
Saudi Arabia (K.S.A.) in the further expansion of its SILVER (Stabilization
In LiVER Failure) clinical trial to the Middle East. The trial is evaluating
whether VTI's biological cellular therapy product, ELAD(R), can prevent
deterioration of liver function and improve the survival of patients with
acute-on-chronic liver failure (ACLF).

The SILVER trial is an open label, multi center, controlled and
randomized trial. To date, 40 subjects have been enrolled at 14 clinical
sites in U.S. (11), U.K. (2) and K.S.A. More than 20 sites should eventually
enroll a total of 80 or more subjects in a 1:1 treated- to-control ratio. If
successful, the resulting data will provide the basis for a Biological
License Application (BLA) in the U.S., a Marketing Approval Application (MAA)
in Europe, and a marketing approval application in K.S.A. For a full listing
of clinical trial sites and further information on the trial, please see
www.clinicaltrials.gov.

National Guard Hospital in Riyadh is one of the few hospitals in the
Middle East to be recognized for the conduct of multi-center international
clinical trials. The Hospital has participated in several multinational
clinical trials in the past. The Principal Investigator in the trial, Dr.
Ahmed Al Jabbary, said, "We are delighted to be a site for the SILVER
clinical trial. Several of our nurses and physicians have been trained in the
conduct of ELAD therapy at VTI's San Diego facility and are ready to assist
in the subject treatments. The logistics of the shipment of the live human
liver cells in the ELAD cartridges have been addressed and we expect to be
treating each subject within 36 hours of shipment of the cartridges from
VTI's plant in San Diego, California".

In addition to being a Expanded Access (compassionate use)SILVER trial
site, National Guard Hospital is also part of VTI's program. One subject has
already been treated in K.S.A. under this program.

The need for liver support therapies in K.S.A. and the Middle East should
be substantial due to the high prevalence of hepatitis A, B and C infection
and the low incidence of liver transplantation in the region. Including an
investigational site in K.S.A. will enable the early submission of a local
marketing application when the trial is completed.

About Vital Therapies, Inc.

Vital Therapies, Inc. (VTI) is based in San Diego, California, with a
wholly owned subsidiary in Beijing, China. VTI is developing the first human
liver cell-based Extracorporeal Liver Assist System (ELAD). ELAD could
provide support for patients with severe liver failure by processing toxins
and synthesizing proteins and metabolites that are key products of normal
human liver function. ELAD is in investigational clinical trials and VTI
completed a pivotal trial and filed for market approval in China in September
2007. For additional information visit www.vitaltherapies.com or
contact Terry Winters, PhD, CEO, Vital Therapies at +1-858-673-6840. ELAD is
a trademark of Vital Therapies, Inc.

About National Guard Hospital

King Fahad National Guard Hospital in Riyadh commenced its operations in
May 1983. Since then, it has continued expanding, while providing services
for a rapidly growing patient population in all of its catchment areas.
Today, King Fahad National Guard Hospital has evolved to be part of the King
Abdulaziz Medical City with many other prominent medical centers. Since its
inauguration in February 2001; and within a short period, KAMC has been
recognized as a distinguished healthcare provider.

KAMC is a JCI accredited healthcare provider and has been re-accredited
recently in December 2009 with the JCI "Gold Seal of Approval" with excellent
results. This is in recognition of KAMC's continual improvement in patient
safety, quality care according to international standards, utilization of
their education and consultation services, and an ability to match
international benchmarks in patient health care.

The Arab Health Exhibition 2010 awarded KAMC "Excellence in Electronic
Health Records Award" in recognition of their outstanding achievements in the
development of quality medical care and high levels of health care services
in the Middle East.

About ELAD and the SILVER Trial

The SILVER protocol enrolls subjects with chronic liver disease who have
been hospitalized as a result of an event, such as an infection or an episode
of bleeding, which has caused deterioration of their liver function
(acute-on-chronic liver failure, ACLF). The trial is designed to explore
whether the use of ELAD in this setting can prevent continued deterioration
of liver function, called progression, and thus improve survival. The trial
design uses a well-established measure of liver function called the MELD
score to define the status of liver function. Treatment with ELAD, along with
standard of care, is compared with standard of care alone. The time to either
death or deterioration of liver function by a pre-specified amount is
measured. It is postulated that the use of ELAD may extend the time to
progression and improve survival in this rapidly progressing patient
population.

ELAD is a biologic liver support system using a proprietary line of
allogeneic human liver cells originally derived from a human liver tumor and
refined by several leading cell experts. The cells are stable, immortal, can
be grown in unlimited quantities and retain their hepatocyte (liver cell)
characteristics. About one pound of cells is used for each treatment. The
cells are grown in specially designed cartridges at VTI's plant in San Diego,
transported to the hospital and used to treat the patient's plasma outside
the body for up to ten days.

Terry Winters, PhD, CEO of Vital Therapies +1-858-673-6840